NEW YORK (GenomeWeb) – Immunexpress said today it has received 510(k) clearance from the US Food and Drug Administration for the use of its Septicyte Lab, an RNA-based blood test that helps clinicians determine whether an infection has caused a patient's systemic inflammation.

Immunexpress noted that being able to rapidly differentiate infection-positive systemic inflammation, or sepsis, from infection-negative systemic inflammation, or systemic inflammatory response syndrome (SIRS), can save lives and reduce healthcare costs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.